-Reuters
Apellis Pharmaceuticals Q2 EPS $(1.46) Misses $(1.36) Estimate, Sales $16.32M Miss $16.94M Estimate
Apellis Pharmaceuticals (NASDAQ:APLS) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate of $(1.36) by 7.35 percent. This is a 46.32 percent increase over losses of $(2.72) per